Murty Pharmaceuticals, Inc.

Lexington, KY

UEI
DNJBTJ3XBQM6
CAGE
3BJ06
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Manufacturer of Goods
  • Subcontinent Asian (Asian-Indian) American Owned
  • Subchapter S Corporation
Entity structure
Corporate Entity (Not Tax Exempt)
Other NAICS codes in SAM.gov
SAM.gov registration date
Physical address
518 Codell Dr, Lexington, KY 40509, USA
Website
mpirx.com
Founded
1995
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $92,724
FY2025 $92,724
FY2024 -$101,913
FY2023 -$11,904

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Department of Health and Human Services $92,724

Contract vehicles

No active vehicles.

2 expired vehicles

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Award Agency Obligated Awarded
Nasal delivery of ondansetron for treatment of alcoholism R43AA016862 National Institutes of Health $0

Similar vendors

About the company

Murty Pharmaceuticals, Inc. is a minority-owned, small disadvantaged business located in Lexington, Kentucky, specializing in pharmaceutical research, development, and manufacturing. Registered in SAM.gov since 2002, the company is structured as a for-profit, Subchapter S Corporation with a focus on developing pharmaceutical products for substance use disorder treatments. As a manufacturer of goods with a specific emphasis on pharmaceutical research, Murty Pharmaceuticals has established itself as a key contractor for federal agencies, particularly in the realm of pharmaceutical development for addiction and substance abuse research.

The company has consistently secured federal contract awards from the National Institute on Drug Abuse (NIDA), primarily performing specialized pharmaceutical research and manufacturing services. These contracts have included critical scientific work such as drug product stability studies, manufacture of specialized pharmaceutical compounds like morphine sulfate pellets, and production of controlled substances for research purposes. Specifically, Murty Pharmaceuticals has completed contracts involving the manufacture of Good Manufacturing Practice (GMP) methamphetamine hydrochloride for intravenous injection and various drug stability studies. Their contract awards, ranging from $88,415 to $245,582, have been consistently awarded without specific small business set-aside designations, indicating the company's competitive capabilities in pharmaceutical research and manufacturing.

Murty Pharmaceuticals holds a significant $7 million single-award indefinite delivery contract with NIDA, effective through September 2026, which serves as the primary vehicle for their federal contract work. This contract enables the company to provide comprehensive pharmaceutical development services, including formulation development, clinical trial materials production, analytical testing, and stability studies for drug products related to substance abuse treatment. The contract's broad scope allows Murty Pharmaceuticals to support NIDA's medications development program for addiction treatment, performing specialized pharmaceutical preparation work that requires precision, scientific expertise, and compliance with FDA regulations. Task orders under this contract have consistently focused on developing pharmaceutical products for treating substance use disorders, highlighting the company's specialized role in supporting critical medical research through sophisticated pharmaceutical manufacturing and development services.

SBA capabilities narrative

Murty Pharmaceuticals, Inc. provides drug formulation development, analytical lab testing, and manufacturing scale up services.

Quick answers

Is Murty Pharmaceuticals, Inc. registered in SAM.gov?

Yes. Murty Pharmaceuticals, Inc.'s SAM.gov registration is active through February 23, 2027.

Which contract vehicles does Murty Pharmaceuticals, Inc. hold?

Murty Pharmaceuticals, Inc. holds a place on 2 federal contract vehicles, including Drug Formulation and Manufacturing Contracts 2019 and NCATS Drug Product Development Studies 2017-2022.

How much has Murty Pharmaceuticals, Inc. received in federal contracts?

Federal contracts obligated $92,724 to Murty Pharmaceuticals, Inc. in fiscal year 2025 and $71,631 in fiscal years 2023 through 2027.

What is Murty Pharmaceuticals, Inc.'s most recent federal award?

Murty Pharmaceuticals, Inc.'s most recent federal contract award is FY24. To 5 - drug product stability studies. POP 9/13/24-9/12/25 (75N95024F00001), from National Institute on Drug Abuse (NIH), on September 13, 2024.

On GovTribe

See Murty Pharmaceuticals, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors